Saturday 17 October 2026
Export ADTX’s income statement to Excel — free account
Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow ADTX
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
37.33 | 81.45 | 622.20 | 258.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.12) | (0.03) | (1.57) | (1.31) | |
P/B ratio |
0.00 | 0.06 | 0.00 | 0.26 | |
Price to Tangible BV |
0.00 | 0.06 | 0.00 | 0.26 | |
EV/Sales |
110.59 | (525.68) | 817.71 | 340.25 | |
EV/EBITDA |
0.00 | 0.09 | 0.00 | 0.00 | |
EV/Operating CF |
(0.09) | 0.06 | (0.21) | (0.18) | |
EV/FCF |
(0.09) | 0.06 | (0.21) | (0.18) | |
Quick Ratio |
0.02 | 0.26 | 0.02 | 0.02 | |
Current Ratio |
0.06 | 0.31 | 0.02 | 0.02 | |
Net Debt/EBITDA |
0.06 | 0.70 | 0.06 | 0.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.29 | 1.52 | 0.10 | 0.33 | |
Capex/Depreciation |
(0.14) | (0.12) | 0.00 | 0.00 | |
Interest Coverage |
(160.96) | (15.58) | (17.79) | (129.80) | |
Research and Development Expense of Revenue |
8,582.79% | 137,150.00% | 96,000.00% | 76,430.00% | |
Selling, General and Administrative Expense of Revenue |
27,193.44% | 1,030,250.00% | 352,657.14% | 538,810.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 47,330.00% | |
Graham Net Nets |
(90.34) | (34.62) | (5.51) | (6.49) | |
Graham Number |
0.00 | 0.00 | 0.00 | 29,270,994.98 | |
Earnings Yield |
665,922.89% | (12,594.08%) | 5,445,964.98% | 1,016,148.73% | |
Free Cash Flow Yield |
(3,481.47%) | (10,182.61%) | (615.75%) | (724.14%) | |
Revenue per Share |
0.60 | 0.29 | 3.50 | 10.00 | |
Operating CF per Share |
(226.67) | (6,604.07) | (11,723.00) | (23,847.00) | |
Capex per Share |
(0.51) | (9.79) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(227.18) | (6,613.86) | (11,723.00) | (23,847.00) | |
Cash per Share |
13.31 | 2,284.71 | 815.00 | 3,237.00 | |
Shareholders Equity per Share |
(1,741.31) | 2,824.07 | (44,296.00) | 119,949.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1,741.31) | 2,824.07 | (44,296.00) | 119,949.00 | |
Free Cash Flow |
(4.59) | (9.26) | (2.34) | (2.38) | |
Working Capital |
(12.49) | (8.40) | (20.24) | (20.15) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
Net Current Asset Value |
(48.23) | (8.74) | (20.24) | (20.26) | |
EV/EBIT |
0.00 | 0.08 | 0.00 | 0.00 | |
Capex to Sales |
0.85 | 34.25 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.58 | — | 0.71 | 0.22 | |
Average Payables |
7.63 | 10.45 | 13.07 | 11.90 | |
Average Inventory |
0.07 | 0.01 | 0.05 | 0.29 | |
Average Assets |
22.56 | 24.33 | 20.82 | 30.53 | |
Average Common Equity |
(9.71) | 2.52 | (2.21) | 9.17 |
Columns are period end dates · fundamentals updated 2 Oct 2026